Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions
Medicina · 19.05.2026 · 62 (5) · 987
DOI: 10.3390/medicina62050987 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medicina, online erschienen am 19.05.2026. Verfasst von Hacer Demir und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyon 03030, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Fluorouracil, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: FLOT is a highly effective first-line treatment for metastatic gastric cancer and offers a favorable safety profile. Clinical studies investigating the FLOT regimen have reported varying outcomes depending on the infusion duration and have highlighted possible differences in complication rates and the efficacy of neoadjuvant therapy. The choice between 24 h or 48 h infusion durations for fluorouracil can be influenced by several factors, such as the patient’s overall health status, their tolerance to treatment, and the specific treatment protocol determined by the medical team. In this study, we aimed to evaluate the effects of different infusion durations (24 and 48 h) on clinical response, toxicity, and survival in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. Materials and Methods: This retrospective multicenter study included 113 patients with gastric or gastroesophageal junction adenocarcinoma who received neoadjuvant FLOT chemotherapy (24 h infusion: n = 28; 48 h infusion: n = 85). Propensity score matching (PSM) was performed to balance baseline characteristics, yielding a matched cohort of 90 patients. The primary endpoints were the pathologic complete response (pCR) and toxicity. Secondary endpoints included disease-free survival (DFS) and overall survival (OS).
Results
Significant baseline imbalances existed (cT stage p < 0.001). After PSM, the balance improved (cT stage p = 0.009). In the matched cohort, pCR 11.1% (24 h) vs. 12.1% (48 h), p > 0.99. The median DFS was 27.4 mo (24 h) vs. NR (48 h), p = 0.847. The median OS was 32.8 mo in both, p = 0.797. Multivariate analysis (baseline variables) indicates that infusion duration is not prognostic (DFS HR = 0.77, p = 0.453; OS HR = 0.72, p = 0.328). Power was ~10% for a 1% pCR difference.
Conclusions
The 24 h infusion protocol was associated with similar outcomes to the 48 h protocol after PSM adjustment. However, residual confounding persists (cT stage p = 0.009 despite PSM), and the combination of this study’s retrospective design and severe underpowering (~10%) precludes definitive conclusions. As a result, the findings are hypothesis-generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyon 03030, Turkey.
- Department of Medical Oncology, Antalya City Hospital, Antalya 07080, Turkey.
- Department of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.
- Department of Medical Oncology, Kayseri Acıbadem Hospital, Kayseri 38030, Turkey.
- Department of Medical Oncology, Van Yüzüncü Yıl University, Van 65080, Turkey.
- Department of Medical Oncology, Alaaddin Keykubat University, Antalya 07425, Turkey.
ORCID-Profile: Canan Yıldız, Yusuf İlhan, Murat Araz, Ali Fuat Gürbüz, Beyza Ünlü, Ramazan Cosar, Meltem Baykara, Ismail Beypinar
Zitieren
APA
Demir, H., Yıldız, C., İlhan, Y., Araz, M., Gürbüz, A. F., Urvay, S., Urun, M., Mermit Ercek, B., Balçık, O. Y., Ünlü, B., Davarcı, S. E., Cosar, R., Baykara, M., & Beypinar, I. (2026). Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions. Medicina, 62(5), 987. https://doi.org/10.3390/medicina62050987
Vancouver
Demir H, Yıldız C, İlhan Y, Araz M, Gürbüz AF, Urvay S, et al. Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions. Medicina. 2026;62(5):987. doi:10.3390/medicina62050987
BibTeX
@article{Demir2026,
author = {Demir, Hacer and Yıldız, Canan and İlhan, Yusuf and Araz, Murat and Gürbüz, Ali Fuat and Urvay, Semiha and Urun, Muslih and Mermit Ercek, Berrak and Balçık, Onur Yazdan and Ünlü, Beyza and Davarcı, Sena Ece and Cosar, Ramazan and Baykara, Meltem and Beypinar, Ismail},
title = {Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions},
journal = {Medicina},
year = {2026},
volume = {62},
number = {5},
pages = {987},
doi = {10.3390/medicina62050987}
}
EUVIMED